Predictive value of PCSK9 gene rs562556 polymorphism for major adverse cardiovascular events after PCI in patients with type 2 diabetes mellitus complicated by acute myocardial infarction
10.12007/j.issn.0258-4646.2025.10.005
- VernacularTitle:PCSK9基因rs562556多态性对2型糖尿病合并急性心肌梗死患者PCI术后主要不良心血管事件的预测价值
- Author:
Yuanyuan LIU
1
;
Qibo CAI
;
Yan QU
;
Xiujing YANG
;
Rongchun GUAN
;
Canjun LIU
Author Information
1. 齐齐哈尔医学院附属第三医院 检验科,黑龙江 齐齐哈尔 161000
- Publication Type:Journal Article
- Keywords:
type 2 diabetes mellitus;
acute myocardial infarction;
gene polymorphism;
percutaneous coronary intervention;
major adverse cardiovascular event
- From:
Journal of China Medical University
2025;54(10):889-895
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive value of PCSK9 gene rs562556 polymorphism for major adverse cardiovascular events(MACE)after percutaneous coronary intervention(PCI)in patients with type 2 diabetes mellitus(T2DM)complicated by acute myocardial infarction(AMI).Methods A total of 97 patients were involved in this study with T2DM complicated by AMI,who underwent PCI at The Third Affiliated Hospital of Qiqihar Medical University between January 2019 and December 2021.Based on MACE occurrence during a 2-year follow-up period,patients were divided into non-MACE group and MACE group(n=57 and 40,respectively).Clinical biochemical parameters,including blood glucose and lipid levels,were recorded.Plasma PCSK9 levels were assessed using enzyme-linked immunosorbent assay.Plasma PCSK9 gene rs562556 polymorphism was detected through sequencing.Kaplan-Meier curve analysis was performed to assess how rs562556 polymorphism impacts MACE incidence post-PCI.Multivariate logistic regression was applied to identify independent MACE-associated risk factors.ROC curve analysis was performed to evaluate the predictive value of rs562556 poly-morphism and key clinical variables for MACE occurrence post-PCI.Results Compared to the non-MACE group,patients in the MACE group exhibited significantly higher age,heart rate,creatinine,NT-proBNP,LDL-C,and plasma PCSK9 levels,along with higher hyper-tension and coronary atherosclerotic heart disease prevalence,and lower diastolic blood pressure(all P＜0.05).In patients with T2DM and AMI,the rs562556 genotype AA of the PCSK9 gene positively correlated with plasma PSCK9 levels(r=0.61,P＜0.000 1).The frequen-cies of the rs562556 genotype AA and allele A were significantly higher in the MACE compared to the non-MACE group(P＜0.05).The AA genotype of the PCSK9 gene rs562556 was associated with an increased risk of MACE during follow-up in patients with T2DM and AMI(P＜0.05).After adjusting for other confounding variables,advanced age,increased NT-proBNP and PCSK9 levels,and the rs562556 AA genotype were identified as independent risk factors for MACE post-PCI in this patient population.Combined analysis of these factors demonstrated superior predictive value for MACE occurrence compared to individual markers.Conclusion The PCSK9 gene rs562556 genotype AA is associated with a significantly increased risk of MACE within two years post-PCI in patients with T2DM and AMI,sug-gesting that it could serve as a promising predictive biomarker for post-PCI MACE in the given population.
